September 2021 – Beroni Group

The 6th China BioMed Innovation and Investment Conference

Beroni Group was invited to attend the 6th China BioMed Innovation and Investment Conference

Post author:tnt
Post published:2021-09-30
Post category:2021
Post comments:0 Comments

September 25-27, 2021, the sixth “China BioMed Innovation and Investment Conference(CBIIC)” was successfully held in Suzhou. With cutting-edge scientific research and advanced medical projects, the scientific research team of Beroni…

Beroni Group Wishing You Happy Mid-Autumn Festival！

Post author:tnt
Post published:2021-09-18
Post category:2021
Post comments:0 Comments

Beroni Group Announced the Latest Clinical Study of its SARS- CoV-2 Antigen Test Kit (Colloidal Gold Method)

Post author:tnt
Post published:2021-09-01
Post category:2021
Post comments:0 Comments

NEW YORK and SYDNEY, Australia, Aug. 31, 2021 -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced the latest clinical study of its SARS-CoV-2 Antigen Test…

Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO

Post author:tnt
Post published:2021-09-01
Post category:2021
Post comments:0 Comments

NEW YORK and SYDNEY, Australia, August 18, 2021 - Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer…

Beroni Group was invited to attend the 6th China BioMed Innovation and Investment Conference

Beroni Group Wishing You Happy Mid-Autumn Festival！

Beroni Group Announced the Latest Clinical Study of its SARS- CoV-2 Antigen Test Kit (Colloidal Gold Method)

Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO

About

Core Businesses

Products

Copyrights© Beroni Group 2019 | All rights reserved |

website by chase e-Design